The United Arab Emirates' centralized pharmaceutical regulator, the Emirates Drug Establishment, has implemented new requirements for medical device distribution networks—a change designed to strengthen supply resilience. Under Federal Decree-Law No. 38 of 2024, which became effective January 2, 2025, companies seeking to sell medical devices in the UAE must now appoint multiple agents to import and distribute the same product. This multi-agent appointment mechanism addresses a fundamental vulnerability: under the previous framework, exclusive distributor arrangements meant that when a single distributor faced delays or operational challenges, availability could become critically constrained. For residents and healthcare providers in the UAE, this restructuring aims to support steadier supply and foster competitive pricing.
Why This Shift Reshapes Healthcare Access
The multi-agent requirement emerged from lessons learned during the COVID-19 pandemic, when concentrated supply chains exposed critical vulnerabilities. Under the old framework, one company held exclusive rights to import and distribute a specific medical device across the emirates. When that distributor faced customs delays, warehouse capacity issues, or other operational challenges, availability became strained. The new decree, which consolidated medical device oversight under the EDE effective January 2, 2025, flipped this dependency model.
Now, a company seeking to sell a device in the United Arab Emirates must designate at least two separate UAE-based pharmaceutical establishments to handle importation and distribution. The practical benefit is redundancy: if one agent encounters obstacles, another can sustain the product line. During the COVID-19 crisis, such safeguards would have reduced critical shortages of ventilators and diagnostic kits. The EDE's regulatory framework clearly prioritizes supply chain resilience as a national objective.
The Regulatory Framework and Compliance Requirements
Federal Decree-Law 38/2024 consolidated medical device regulation under the EDE by December 2025, creating a centralized authority for product registration, renewals, variations, import permits, and post-market surveillance. Previously, approvals split between the Ministry of Health and Prevention (MOHAP) federally and the Department of Health Abu Dhabi locally—a dual-approval process that added complexity and timelines.
The consolidation aims to streamline submissions through the EDE's digital portal (ede.gov.ae). However, the regulator's expanded mandate—now covering medical devices, biopharmaceuticals, food supplements, cosmetics, and genetically modified organisms for medical use—has increased the scope of oversight significantly.
Foreign manufacturers entering the UAE market must appoint a UAE-based Local Authorized Representative (LAR) before submitting product applications. The LAR assumes legal accountability for the device in the UAE, including adverse event reporting and documentation. Additionally, manufacturing sites must be pre-registered with the EDE before filing product dossiers.
Stakeholder Engagement and Implementation
In June 2026, the EDE convened a virtual Customer Council session to review the multi-agent appointment feature with manufacturers' agents, medical warehouse operators, and marketing offices. This session provided stakeholders an opportunity to discuss implementation of the already-active multi-agent requirement and explore ways to improve efficiency in the registration and compliance processes.
Industry participants raised several implementation considerations: clarification on approval timelines, enhanced documentation guidance, and practical guidance on multi-agent contract architecture. These discussions reflect the ongoing dialogue between regulators and industry as the framework matures. The EDE continues to conduct quarterly Customer Council meetings where stakeholders can discuss specific implementation questions.
Supply Chain Resilience Potential and Market Realities
Hospitals and clinics across the United Arab Emirates theoretically benefit from the multi-agent mandate through increased competition and improved availability. When multiple agents bid for medical device contracts, procurement teams can negotiate pricing and delivery commitments more competitively. This is particularly significant for capital-intensive purchases such as diagnostic or surgical equipment, where even modest price improvements translate to meaningful savings for healthcare budgets.
However, market dynamics vary by product category. A device commanding substantial demand across the UAE can justify appointing multiple agents. Conversely, niche therapeutic devices with limited patient populations may struggle to attract secondary distributors, potentially leaving authorization holders dependent on fewer agents despite the mandate. Supply chain improvements will inevitably depend on market scale and demand for specific products.
The regulatory framework places responsibility on marketing authorization holders to monitor compliance across all appointed agents, compile required safety reports, and maintain accurate documentation. This coordination burden scales with a company's product portfolio, requiring robust administrative systems to track renewals, submissions, and regulatory timelines.
What Comes Next: Compliance and Regulatory Development
Companies affected by Federal Decree-Law 38/2024 are now operating under full compliance requirements, with the EDE prioritizing enforcement of multi-agent appointments, documentation accuracy, and post-market surveillance during 2026 inspections.
For foreign manufacturers, the operational path is clear: engage a knowledgeable UAE-based Local Authorized Representative, pre-register manufacturing sites on the EDE portal, and maintain compliance with pharmacovigilance and documentation requirements. Smaller market entrants may benefit from regional representation services that manage these administrative functions.
As the regulatory framework stabilizes through 2027, the United Arab Emirates is positioning itself as a globally competitive pharmaceutical hub, balancing rigorous safety standards with market accessibility. The multi-agent appointment requirement reflects this broader strategy to enhance supply chain resilience while maintaining regulatory oversight. The practical effectiveness of this mechanism will become clearer as implementation matures and market stakeholders adapt to the new requirements.
